TScan Therapeutics (TCRX) Invested Capital (2023 - 2024)

TScan Therapeutics' (TCRX) quarterly Invested Capital came in at $10.3 million in Q2 2024, up 52.07% on a QoQ basis from $6.8 million in Q1 2024.

TScan Therapeutics (TCRX) Invested Capital (2023 - 2024) Analysis & Trends

TScan Therapeutics (TCRX) has 2 years of Invested Capital data on file, last reported at $10.3 million in Q2 2024.

On a quarterly basis, Invested Capital changed N/A year-over-year to $10.3 million in Q2 2024; TTM through Mar 2025 was $10.3 million, a 8.16% decrease from a year earlier, with the FY2023 full-year figure at $3.3 million, changed N/A from the prior year.
Invested Capital for Q2 2024 stood at $10.3 million, up from $6.8 million in the prior quarter.
Over the last five years, Invested Capital for TCRX reached as high as $10.3 million in Q2 2024 and fell as low as $1.1 million in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	110.96 Mn
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	116.14 Mn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	-
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	TScan Therapeutics	100.59 Mn	-27.47 Mn	-	-

Download Data